Clinical Features and Differential Diagnoses of Kawasaki Disease

Kawasaki disease is a rare but serious condition that primarily affects children under the age of five. To diagnose Kawasaki disease, a patient must have a fever for at least five days and four out of five classical features: bilateral, non-exudative conjunctival injection, changes in lips and oral cavity, oedema and erythema in the hands and feet, polymorphous rash, and cervical lymphadenopathy. However, tonsillar exudate, leukopenia, neck stiffness, and small submental lymph nodes are not classical features of Kawasaki disease and should prompt consideration of other differential diagnoses. Patients with confirmed Kawasaki disease should undergo echocardiographic examination to detect potential coronary artery aneurysms. Early diagnosis and treatment are crucial to prevent serious complications.

The most probable diagnosis for this patient is lateral epicondylitis, which is characterized by pain around the lateral epicondyle of the humerus that radiates to the forearm. The pain is exacerbated by repetitive movements with the dominant hand, which is common in the patient’s job as a cleaner. The pain is worsened by resisted wrist extension and supination while the elbow is extended. Medial epicondylitis, olecranon bursitis, radial head fractures, and septic arthritis are less likely differentials as they do not match the examination findings in this scenario.

Understanding Lateral Epicondylitis

Lateral epicondylitis, commonly known as tennis elbow, is a condition that often occurs after engaging in activities that the body is not accustomed to, such as painting or playing tennis. It is most prevalent in individuals aged 45-55 years and typically affects the dominant arm. The primary symptom of this condition is pain and tenderness localized to the lateral epicondyle. The pain is often exacerbated by wrist extension against resistance with the elbow extended or supination of the forearm with the elbow extended. Episodes of lateral epicondylitis can last between 6 months and 2 years, with patients experiencing acute pain for 6-12 weeks.

To manage lateral epicondylitis, it is essential to avoid muscle overload and engage in simple analgesia. Steroid injections and physiotherapy are also viable options for managing the condition. By understanding the symptoms and management options for lateral epicondylitis, individuals can take the necessary steps to alleviate pain and discomfort associated with this condition.

Diagnostic Tests for Pulmonary Embolism: A Comparison

Pulmonary embolism (PE) is a serious medical condition that requires prompt diagnosis and treatment. There are several diagnostic tests available for PE, but not all are equally effective. Here, we compare the most commonly used tests and their suitability for diagnosing PE.

CT pulmonary angiogram (CTPA) is the gold standard diagnostic test for PE. It is highly sensitive and specific, making it the most definitive investigation for PE. Patients with a history of recent surgery and subsequent symptoms pointing towards PE should undergo a CTPA.

Electrocardiography (ECG) is not a first-line diagnostic test for PE. Although classic ECG changes may occur in some patients with PE, they are not specific to the condition and may also occur in individuals without PE.

Chest radiograph is less definitive than CTPA for diagnosing PE. While it may show some abnormalities, many chest radiographs are normal in PE. Therefore, it is not a reliable test for diagnosing PE.

Echocardiogram may show right-sided heart dysfunction in very large PEs, but it is not a first-line diagnostic test for PE and is not definitive in the investigation of PE.

Positron emission tomography (PET)/CT of the chest is not recommended for the investigation of PE. It is a radioisotope functional imaging technique used in the imaging of tumours and neuroimaging, but not for diagnosing PE.

In conclusion, CTPA is the most definitive diagnostic test for PE and should be used in patients with a high suspicion of the condition. Other tests may be used in conjunction with CTPA or in specific cases, but they are not as reliable or definitive as CTPA.

Understanding SIADH: The Syndrome of Inappropriate Antidiuretic Hormone Secretion

SIADH, or the syndrome of inappropriate antidiuretic hormone secretion, is a condition where the body produces too much vasopressin (ADH), leading to overhydration in both the intracellular and extracellular compartments. This can result in dilutional hyponatraemia, where the sodium concentration falls to dangerous levels. Symptoms may include drowsiness, lethargy, irritability, mental confusion, and disorientation, with seizures and coma being the most severe features.

SIADH can develop as a paraneoplastic syndrome, most commonly in patients with small-cell carcinoma of the lung. However, it can also be associated with various other neoplastic and non-neoplastic pathologies, as well as certain medications. Treatment for SIADH may involve restriction of fluids, demeclocycline, or other interventions, but caution must be taken to avoid complications such as cardiac failure, cerebral oedema, or central pontine myelinolysis.

While a sodium-restricted diet or sodium-reduced water drinking may contribute to hyponatraemia, they are unlikely to cause such severe levels in the absence of other medical conditions. Liver metastases and bone metastases may also be associated with hyponatraemia, but in the context of a known diagnosis of small-cell lung cancer, SIADH is the most likely explanation.

Overall, understanding SIADH and its potential causes and treatments is crucial for managing hyponatraemia and preventing serious complications.

Treatment Options for Atrial Fibrillation: A Comprehensive Guide

Atrial fibrillation (AF) is a common cardiac arrhythmia that requires prompt and appropriate management to prevent complications. Here are some treatment options for AF:

Rate Control: This is recommended for patients who have had AF for more than 48 hours. Beta-blockers are the first-line treatment unless there is a contraindication such as asthma. Calcium channel blockers can also be used.

Digoxin: This drug can be used as rate control if the patient cannot have beta-blockers or calcium channel blockers. However, it should only be used as a third-line treatment or as an adjunct because it has been shown to increase mortality. It is also only effective in sedentary patients.

DC Cardioversion: This can be used to treat new-onset AF if the patient has had it for less than 48 hours. It can also be considered in patients who have had it for longer than that, once they have been on stable anticoagulation for at least 3 weeks.

Flecainide: This is a class Ic antiarrhythmic drug that can be used as chemical cardioversion in new AF (<48 hours) or if a patient has been anticoagulated for >3 weeks.

Rhythm Control: Nice guidelines advise that rhythm control can be used if AF onset was <48 hours ago, but should be avoided if longer ago because it can increase the risk of stroke from an atrial thrombus. In longer cases, rate control should be used, which is with beta-blockers or rate-limiting calcium channel blockers. Digoxin can be used third line or as an adjunct. In conclusion, the appropriate treatment for AF depends on the duration of the arrhythmia, the patient’s comorbidities, and other factors. It is important to consult with a healthcare professional to determine the best course of action.

If a patient is taking aminosalicylates, they may experience various haematological adverse effects, such as agranulocytosis. Therefore, it is crucial to conduct a full blood count promptly if the patient presents with symptoms like fever, fatigue, bleeding gums, or a sore throat to rule out agranulocytosis. While C-reactive protein may be a part of the overall management plan, it is not the most critical initial investigation and is unlikely to alter the management plan. Similarly, while a throat swab may be necessary, it is not the most crucial initial investigation. The monospot test for glandular fever may be useful if glandular fever is suspected, but it is not the most important initial investigation.

Aminosalicylate drugs, such as 5-aminosalicyclic acid (5-ASA), are released in the colon and act locally as anti-inflammatories. The exact mechanism of action is not fully understood, but it is believed that 5-ASA may inhibit prostaglandin synthesis. Sulphasalazine is a combination of sulphapyridine and 5-ASA, but many of its side-effects are due to the sulphapyridine component, including rashes, oligospermia, headache, Heinz body anaemia, megaloblastic anaemia, and lung fibrosis. Other side-effects are common to 5-ASA drugs, such as mesalazine, which is a delayed release form of 5-ASA that avoids the sulphapyridine side-effects seen in patients taking sulphasalazine. However, mesalazine is still associated with side-effects such as gastrointestinal upset, headache, agranulocytosis, pancreatitis, and interstitial nephritis. Olsalazine is another aminosalicylate drug that consists of two molecules of 5-ASA linked by a diazo bond, which is broken by colonic bacteria.

It is important to note that aminosalicylates are associated with various haematological adverse effects, including agranulocytosis, and a full blood count (FBC) is a key investigation in an unwell patient taking them. Additionally, pancreatitis is seven times more common in patients taking mesalazine than in those taking sulfasalazine.

To avoid reduced absorption of levothyroxine, iron/calcium carbonate tablets should be administered four hours apart.

Managing Hypothyroidism: Dosage, Monitoring, and Side-Effects

Hypothyroidism is a condition where the thyroid gland does not produce enough thyroid hormone. The main treatment for hypothyroidism is levothyroxine, a synthetic form of thyroid hormone. When managing hypothyroidism, it is important to consider the patient’s age, cardiac history, and initial starting dose. Elderly patients and those with ischaemic heart disease should start with a lower dose of 25mcg od, while other patients can start with 50-100mcg od. After a change in dosage, thyroid function tests should be checked after 8-12 weeks to ensure the therapeutic goal of normalising the thyroid stimulating hormone (TSH) level is achieved. The target TSH range is 0.5-2.5 mU/l.

Women with hypothyroidism who become pregnant should have their dose increased by at least 25-50 micrograms levothyroxine due to the increased demands of pregnancy. The TSH should be monitored carefully, aiming for a low-normal value. It is important to note that there is no evidence to support combination therapy with levothyroxine and liothyronine.

While levothyroxine is generally well-tolerated, there are some potential side-effects to be aware of. Over-treatment can lead to hyperthyroidism, while long-term use can reduce bone mineral density. In patients with cardiac disease, levothyroxine can worsen angina and lead to atrial fibrillation. It is also important to be aware of drug interactions, particularly with iron and calcium carbonate, which can reduce the absorption of levothyroxine. These medications should be given at least 4 hours apart.

In summary, managing hypothyroidism involves careful consideration of dosage, monitoring of TSH levels, and awareness of potential side-effects and drug interactions. With appropriate management, patients with hypothyroidism can achieve normal thyroid function and improve their overall health.

The RCGP has previously provided feedback that doctors are required to have knowledge of emergency medication dosages, with a specific emphasis on suspected cases of meningococcal septicaemia.

Paediatric Drug Doses for Emergency Situations

When it comes to prescribing drugs for children in emergency situations, it is important to consult the current British National Formulary (BNF) beforehand. However, as a guide, the following doses can be used for intramuscular (IM) benzylpenicillin in suspected cases of meningococcal septicaemia in the community. For children under one year old, the dose is 300 mg. For children between one and ten years old, the dose is 600mg. For children over ten years old, the dose is 1200mg. It is important to note that these doses are only a guide and should be adjusted based on the individual child’s weight and medical history. Always consult with a healthcare professional before administering any medication to a child.

Patients with HIV infection commonly experience diarrhoea as a result of Cryptosporidium, while respiratory infection may be caused by Histoplasmosis.

Diarrhoea in HIV Patients: Causes and Management

Diarrhoea is a common symptom experienced by patients with HIV. It can be caused by the virus itself, known as HIV enteritis, or by opportunistic infections. The most common infective cause of diarrhoea in HIV patients is Cryptosporidium, an intracellular protozoa with an incubation period of 7 days. Symptoms can range from mild to severe diarrhoea, and diagnosis is made through a modified Ziehl-Neelsen stain of the stool. Unfortunately, treatment is difficult, and supportive therapy is the mainstay of management.

Other possible causes of diarrhoea in HIV patients include Cytomegalovirus, Mycobacterium avium intracellulare, and Giardia. Mycobacterium avium intracellulare is an atypical mycobacteria that is typically seen when the CD4 count is below 50. Symptoms include fever, sweats, abdominal pain, and diarrhoea, and diagnosis is made through blood cultures and bone marrow examination. Management involves the use of rifabutin, ethambutol, and clarithromycin.

In summary, diarrhoea is a common symptom experienced by HIV patients, and it can be caused by a variety of opportunistic infections. While treatment can be difficult, supportive therapy can help manage symptoms. It is important for healthcare providers to be aware of the potential causes of diarrhoea in HIV patients and to work with their patients to develop an appropriate management plan.

Understanding the CURB-65 Score for Mortality Prediction in Pneumonia

Pneumonia is a serious respiratory infection that can lead to mortality, especially in older patients. Several factors can increase the risk of death, including elevated urea levels, low blood pressure, leukopenia, and atrial fibrillation. To predict mortality in pneumonia, healthcare professionals use the CURB-65 score, which considers five parameters: confusion, urea >7 mmol/l, respiratory rate >30/min, systolic blood pressure <90 mmHg or diastolic blood pressure <60 mmHg, and age >65 years. Each parameter scores a point, and the higher the total score, the higher the associated mortality.

Based on the CURB-65 score, healthcare professionals can make informed decisions about treatment and admission to hospital. Patients with a score of 0 or 1 can be treated at home with oral antibiotics, while those with a score of 2 should be considered for hospital admission. Patients with a score of 3 or higher should be admitted to hospital, and those with a score of 4-5 may require high dependency or intensive therapy unit admission. However, individual circumstances, such as the patient’s performance status, co-morbidities, and social situation, should also be considered when making treatment decisions.

In summary, the CURB-65 score is a valuable tool for predicting mortality in pneumonia and guiding treatment decisions. By considering multiple factors, healthcare professionals can provide the best possible care for patients with this serious infection.